Amedeo Smart

Free Medical Literature Service

 

Amedeo

Vaccines
  Free Subscription

10.11.2025

2 BMJ
2 Infect Immun
3 J Virol
1 JAMA
1 N Engl J Med
1 PLoS Med
5 PLoS One
4 Proc Natl Acad Sci U S A
1 Science
17 Vaccine
1 Virus Res


    BMJ

  1. WISE J
    Covid-19: Major study compares myocarditis risk in children after vaccination or infection.
    BMJ. 2025;391:r2330.
    >> Share

  2. WISE J
    RFK Jr urges world to follow US's lead on mercury in vaccines.
    BMJ. 2025;391:r2335.
    >> Share


    Infect Immun

  3. ZHANG W, Sack DA
    Recent progress in enterotoxigenic Escherichia coli vaccine research and development.
    Infect Immun. 2025 Nov 6:e0036825. doi: 10.1128/iai.00368.
    >> Share

  4. HEINZEN RA, Pierce KN, Voth DE, Stenos J, et al
    Control of human Q fever by vaccination: the journey to Q-VAX and beyond.
    Infect Immun. 2025 Nov 6:e0028025. doi: 10.1128/iai.00280.
    >> Share


    J Virol

  5. SUN Y, Xu S-J, Zhou Y, Zhang Y, et al
    A glycoprotein D-targeted lipid nanoparticle-encapsulated mRNA vaccine elicits strong protective immunity against pseudorabies virus.
    J Virol. 2025 Nov 6:e0147225. doi: 10.1128/jvi.01472.
    >> Share

  6. IRELAND J, Myers D, Huang C, Allen C, et al
    Vaccination protects against COVID-associated pulmonary fibrin deposition.
    J Virol. 2025 Nov 6:e0063325. doi: 10.1128/jvi.00633.
    >> Share

  7. CHANG LA, Yeung ST, Warang P, Noureddine M, et al
    Transient lung eosinophilia during breakthrough influenza infection in vaccinated mice is associated with protective and balanced Type 1/2 immune responses.
    J Virol. 2025 Nov 5:e0096525. doi: 10.1128/jvi.00965.
    >> Share


    JAMA

  8. PANT S
    New COVID-19 Vaccination Guidelines for Immunocompromised Individuals.
    JAMA. 2025 Nov 7. doi: 10.1001/jama.2025.19727.
    >> Share


    N Engl J Med

  9. MALKIN E, Zaric M, Kieh M, Baden LR, et al
    Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate.
    N Engl J Med. 2025;393:1807-1818.
    >> Share


    PLoS Med

  10. JIAO B, Sato R, Mak J, Patenaude B, et al
    Financial risk protection from vaccines in 52 Gavi-eligible low- and middle-income countries: A modeling study.
    PLoS Med. 2025;22:e1004764.
    >> Share


    PLoS One

  11. KOSTRZEWA M, Sadat Seyyedsalehi M, Godono A, Collatuzzo G, et al
    Cancer Prevention at Work (CPW) project: Rationale, framework and research protocol.
    PLoS One. 2025;20:e0335752.
    >> Share

  12. POWELL A, Van Hout MC, Connors D, Montgomery C, et al
    A thematic analysis of flu vaccine hesitance in ethnically minoritised communities in Liverpool.
    PLoS One. 2025;20:e0333602.
    >> Share

  13. AYOUNI I, Githaiga JN, Amponsah-Dacosta E, Kagina BM, et al
    Adapting the WHO Behavioural and Social Drivers of Vaccination (BeSD) tools and Vaccination Attitudes Examination (VAX) scale for pregnant women in South Africa: Insights from a mixed-methods pilot study.
    PLoS One. 2025;20:e0334854.
    >> Share

  14. FEKRI M, Bolhassani A, Movahedi M, Rahmati F, et al
    Simultaneous efficacy of IL-15 and the HSP70 fragments in increasing immunostimulatory effects of a HIV-1 DNA vaccine candidate against SCR HIV-1.
    PLoS One. 2025;20:e0336042.
    >> Share

  15. LI C, Zhu Y, Qi X, Chai Z, et al
    Design of a multi-epitope recombinant BCG vaccine targeting Brucella OMP31, LptE and VirB2 in immunoinformatics approaches.
    PLoS One. 2025;20:e0334843.
    >> Share


    Proc Natl Acad Sci U S A

  16. TATARA AM, Lightbown S, Kang S, Jung WH, et al
    Scaffold vaccination for prevention of orthopedic device infection.
    Proc Natl Acad Sci U S A. 2025;122:e2409562122.
    >> Share

  17. CHO E, Davis MA, Nowak JA, Izzo M, et al
    Modulating antigen processing through metal-organic frameworks to bias adaptive immunity.
    Proc Natl Acad Sci U S A. 2025;122:e2409555122.
    >> Share

  18. SONG K, Nguyen DC, Wang Y, Jokonya S, et al
    Peptide vaccine formulations with structurally distinct STING agonist drugamers induce discrete, efficacious antitumor responses.
    Proc Natl Acad Sci U S A. 2025;122:e2409978122.
    >> Share

  19. HAAS CM, Jasti N, Dosey A, Allen JD, et al
    From sequence to scaffold: Computational design of protein nanoparticle vaccines from AlphaFold2-predicted building blocks.
    Proc Natl Acad Sci U S A. 2025;122:e2409566122.
    >> Share


    Science

  20. ZHANG H, Liu H, Xu Y, Huang H, et al
    Deep generative models design mRNA sequences with enhanced translational capacity and stability.
    Science. 2025 Aug 28:eadr8470. doi: 10.1126/science.adr8470.
    >> Share


    Vaccine

  21. LIU D, Zhang Y, Lei J, Li J, et al
    Influenza, pneumococcal, COVID-19 vaccine willingness and uptake with influencing factors in 38,184 chinese older adults in 2022: a nationwide cross-sectional study.
    Vaccine. 2025;68:127961.
    >> Share

  22. NETT RJ, Brault AC, Lambert AJ, Agnihothram S, et al
    Summary of human West Nile virus vaccine meeting, 2024: Investigating barriers to development.
    Vaccine. 2025;68:127938.
    >> Share

  23. SHARFF KA, Haslam A, Nealon J
    COVID-19 vaccine variant target: how should we choose?
    Vaccine. 2025;68:127917.
    >> Share

  24. DE MELO ARAUJO AC, Frugoli AG, de Sena Goncalves JE, Percio J, et al
    Corrigendum to "Monitoring strategies after the incorporation of vaccines into national immunization programs: a systematic review" [Vaccine 66 (2025) 127850].
    Vaccine. 2025;68:127929.
    >> Share

  25. HAMASHIMA Y, Breheny K, Davies SR, Dawson S, et al
    A synthesis of economic data from randomized trials of recipient-focused interventions to increase vaccine uptake.
    Vaccine. 2025;68:127906.
    >> Share

  26. WU Y, Ren B, Gao X, Li N, et al
    Evaluation of the immunization effects of needle-free injection for four common porcine vaccines.
    Vaccine. 2025;68:127943.
    >> Share

  27. SENDERS S, Korbal P, Kline M, Tamimi N, et al
    Immunogenicity and safety of concomitant vaccines given with 20-valent pneumococcal conjugate vaccine in healthy infants.
    Vaccine. 2025;68:127916.
    >> Share

  28. RHYNE PW, Sunshine J, Hogrefe W, Roscia G, et al
    Development and qualification of a multiplexed immunoassay to assess the immunogenicity of Shigella vaccines.
    Vaccine. 2025;68:127896.
    >> Share

  29. THAWEETHAI T, Gross RS, Pant DB, Rhee KE, et al
    Preventive effect of vaccination on long COVID in adolescents with SARS-CoV-2 infection.
    Vaccine. 2025;68:127907.
    >> Share

  30. BATMUNKH T, Neal EFG, Amraa O, Mazarakis N, et al
    Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial.
    Vaccine. 2025;66:127840.
    >> Share

  31. NAKAHIRA A, Iwaoka H, Sato K, Ishizuka S, et al
    NKT cell-dependent PspA-specific IgA production caused by mucosal administration of a novel nanoparticle pneumococcal vaccine.
    Vaccine. 2025;68:127911.
    >> Share

  32. YU SL, Chung NH, Chen YC, Ho HM, et al
    Natural killer T cells play a significant role in preventing Coxsackievirus A10 infection through an adeno-based vaccine expressing enterovirus-like particles.
    Vaccine. 2025;68:127909.
    >> Share

  33. SALINES M, Andraud M, Scoizec A, Schmitz A, et al
    To what extent may the duck population be protected after vaccination against highly pathogenic avian influenza? Contributions from a modelling approach and French field data.
    Vaccine. 2025;68:127905.
    >> Share

  34. LAMBACH P, Silal S, Sbarra AN, Koh M, et al
    Report from the World Health Organization's Immunization and Vaccines-related Implementation Research Advisory Committee (IVIR-AC) meeting, virtual gathering, 1-5 September 2025.
    Vaccine. 2025;68:127903.
    >> Share

  35. MEMIRIE ST, Teka T, Mekasha A, Alemayehu T, et al
    Prioritization of future new vaccines introduction: The experience of the Ethiopian National Immunization Technical Advisory Group.
    Vaccine. 2025;68:127932.
    >> Share

  36. MAHAJAN M, Martin LB, Gaurav K, Suri RK, et al
    Adaptive clinical trial designs for rapid vaccine development: Developing country vaccine manufacturers' perspective.
    Vaccine. 2025;68:127890.
    >> Share

  37. MORRIS SE, O'Halloran A, Sundaresan D, Dawood FS, et al
    Heterogeneity in seasonal influenza vaccination opportunity and disease risk during pregnancy and in infants <6 months.
    Vaccine. 2025;68:127887.
    >> Share


    Virus Res

  38. CAO W, Li J, Yang F, Zhu Z, et al
    Comparative investigation into the immune efficiency of the single intradermal and intramuscular delivery of foot-and-mouth disease inactivated vaccine in swine.
    Virus Res. 2025 Nov 3:199656. doi: 10.1016/j.virusres.2025.199656.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016